

Resource Summary Report

Generated by [NIF](#) on Sep 15, 2026

Chordoma Foundation

RRID:SCR_013079

Type: Tool

Proper Citation

Chordoma Foundation (RRID:SCR_013079)

Resource Information

URL: <http://www.chordomafoundation.org/>

Proper Citation: Chordoma Foundation (RRID:SCR_013079)

Description: The Chordoma Foundation is an international nonprofit organization working to improve the lives of chordoma patients by accelerating the development of effective treatments, and by helping patients to get the best care possible. Guided by a comprehensive research roadmap, the Foundation initiates and funds research, facilitates information exchange and collaboration among researchers, and provides scientific resources needed for research. Chordoma is a relentless and difficult to treat bone cancer that occurs in the head and spine in people of all ages. No drugs are approved to treat chordoma and the average survival after diagnosis is 7 years; a statistic we are determined to improve. Our Approach: * Fund results-oriented research: We proactively fund research projects identified by our Scientific Advisory Board as strategic priorities for advancing the development of new treatments for chordoma. * Provide scientific resources: We create, collect, store, and distribute the information and biological materials that researchers need in order to study chordoma and develop new treatments. * Facilitate communication and collaboration: We connect physicians, scientists and companies from across the world to share information and collaborate on projects they can only achieve together. * Guide patients to obtain quality care: We provide accurate information about treatment options and clinical trials, refer patients to experienced doctors, and match patients with trained peer-support mentors.

Abbreviations: Chordoma Foundation

Resource Type: institution

Resource Name: Chordoma Foundation

Resource ID: SCR_013079

Alternate IDs: grid.470372.5, Crossref funder ID: 100009272, nlx_38016

Alternate URLs: <https://ror.org/01vpcr438>

Record Creation Time: 20220129T080314+0000

Record Last Update: 20260912T195758+0000

Ratings and Alerts

No rating or validation information has been found for Chordoma Foundation.

No alerts have been found for Chordoma Foundation.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Baluszek SP, et al. (2026) From Histology to Multi-Omics: Review of Chordoma Classification and Its Clinical Implications. *Cells*, 15(9).

He S, et al. (2026) Artificial intelligence chatbots in response to patient's common inquiries about chordoma: A cross-sectional study. *Brain & spine*, 6, 106109.

Cottone L, et al. (2025) ATF4-mediated stress response as a therapeutic vulnerability in chordoma. *Molecular oncology*.

Seeling C, et al. (2025) Cucurbitacin B Exhibits Antitumor Effects on Chordoma Cells via Disruption of Brachyury. *International journal of molecular sciences*, 26(8).

Gao J, et al. (2025) RAB3B Dictates mTORC1/S6 Signaling in Chordoma and Predicts Response to mTORC1-Targeted Therapy. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(19), e2415384.

Yin H, et al. (2024) Clinical-proteomic classification and precision treatment strategy of chordoma. *Cell reports. Medicine*, 5(10), 101757.

Khan S, et al. (2024) Organelle resolved proteomics uncovers PLA2R1 as a novel cell surface marker required for chordoma growth. *Acta neuropathologica communications*, 12(1), 39.

Lilly JV, et al. (2023) The children's brain tumor network (CBTN) - Accelerating research in pediatric central nervous system tumors through collaboration and open science. *Neoplasia (New York, N.Y.)*, 35, 100846.

Seeling C, et al. (2021) Molecular features and vulnerabilities of recurrent chordomas. *Journal of experimental & clinical cancer research* : CR, 40(1), 244.

Cottone L, et al. (2020) Frequent alterations in p16/CDKN2A identified by immunohistochemistry and FISH in chordoma. *The journal of pathology. Clinical research*, 6(2), 113.

Zhou Y, et al. (2019) The clinical outcomes for chordomas in the cranial base and spine: A single center experience. *Medicine*, 98(23), e15980.

Charest-Morin R, et al. (2019) Primary Bone Tumor of the Spine-An Evolving Field: What a General Spine Surgeon Should Know. *Global spine journal*, 9(1 Suppl), 108S.

J??ger D, et al. (2017) HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and sacral chordomas. *Scientific reports*, 7(1), 2032.

Bosotti R, et al. (2017) Establishment and genomic characterization of the new chordoma cell line Chor-IN-1. *Scientific reports*, 7(1), 9226.

Tarpey PS, et al. (2017) The driver landscape of sporadic chordoma. *Nature communications*, 8(1), 890.

Heery CR, et al. (2016) Chordoma: The Quest for Better Treatment Options. *Oncology and therapy*, 4(1), 35.

Gupta S, et al. (2016) A Platform for Designing Genome-Based Personalized Immunotherapy or Vaccine against Cancer. *PloS one*, 11(11), e0166372.

Scheipl S, et al. (2016) EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. *The Journal of pathology*, 239(3), 320.

Patel P, et al. (2014) Investigating microenvironmental regulation of human chordoma cell behaviour. *PloS one*, 9(12), e115909.

Nibu Y, et al. (2013) From notochord formation to hereditary chordoma: the many roles of Brachyury. *BioMed research international*, 2013, 826435.